REVIEW ARTICLE JPAR 2023

Journal of Pharmaceutical Advanced Research
(An International Multidisciplinary Peer Review Open Access monthly Journal)
Available online at: www.jparonline.com

mTOR Signalling pathway in Drug Discovery of Anticancer agents

Esha Panda*, Jyotiprakash Bhanja, Rabinarayan Rana, Bimalendu Chowdhury, B.V.V. Ravi Kumar

Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur-760010, Ganjam, Odisha, India.

Received: 20.02.2023 Revised: 04.04.2023 Accepted: 14.04.2023 Published: 30.04.2023

ABSTRACT: The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is generally assembled into several complexes similar to mTOR complex1/2 (mTORC1/2). The crucial factor in mTORC1 or mTORC2 is mTOR which catalyzes the phosphorylation of multiple targets similar to ribosomal protein S6 kinase β-1 (S6K1), AKT, and Protein Kinase C. Studies have shown that the mTOR signalling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other conditions and activation of mTOR promotes tumour growth and metastasis. It also plays an important part in tumour metabolism in addition to regulating cell proliferation and vulnerable cell isolation. Thus, the mTOR signalling pathway is a hot target in anti-tumour remedy exploration. Numerous mTOR inhibitors have been developed to treat cancer. While some of the mTOR inhibitors have been approved to treat mortal cancer, more mTOR inhibitors are being estimated in clinical trials. The purpose of this review is to introduce the part of the mTOR signalling pathway on apoptosis, autophagy, growth, and metabolism of tumour cells, and to introduce the exploration progress of mTOR inhibitors in the tumour field.

Corresponding author:
Ms. Esha Panda
Research Scholar
Roland Institute of Pharmaceutical Sciences,
Khodasingi, Berhampur-760010,
Ganjam, Odisha, India.
Tel: 91-8280252401
E. Mail ID: eshapanda176@gmail.com

Keywords: mTOR signalling pathway, Rapamycin, mTOR Complex, Cancer.

INTRODUCTION:

The mechanistic target of rapamycin (mTOR) is a dual-specificity protein kinase phosphorylating serine/ threonine as well as tyrosine remainders [1]. It plays a crucial part in tumour tumourigenesis and development through different mechanisms including the creation of growth factor receptor signalling, angiogenesis, glycolytic metabolism, lipid metabolism, cancer cell migration, and repression of autophagy [2]. mTOR catalyses the phosphorylation of multiple targets similar to ribosomal protein S6 kinase β-1(S6K1), eukaryotic translation inauguration factor 4E binding protein 1 (4E-BP1), AKT, protein kinase C (PKC), and type-I insulin-

like growth factor receptor (IGF-IR), thereby regulating protein synthesis, nutrients metabolism, growth factor signalling, cell growth, and migration. It plays a part in transcription and protein synthesis by integrating various signal stimulation and eventually regulates apoptosis, growth, and autophagy of cells [3]. Multiple studies have also suggested that tumours generally activate the AKT/ mTOR signalling pathway [4]. Scientists have also linked the upregulation of mTOR to various complaint processes similar to tumour conformation, arthritis, insulin resistance and osteoporosis [5]. The de-regulated exertion of mTOR is involved in numerous pathophysiological conditions, similar as ageing, Alzheimer's disease, diabetes, obesity and cancer. Thus, mTOR inhibitors are extensively used in the exploration of targeted remedies for tumours, organ transplantation, rheumatoid arthritis, and other conditions. The mTOR forms two structurally and functionally different complexes called the mammalian target of rapamycin complex 1 (mTORC1) and the mammalian target of rapamycin complex 2 (mTORC2). mTOR and mammalian murderous with SEC13 protein 8 (mLST8) are common members of both mTORC1 and mTORC2 while nonsupervisory- associated protein of mTOR (raptor), the 40 kDa proline-rich Akt substrate (PRAS 40), and DEP sphere-containing protein 6(DEPTOR) are specific members of mTORC1. Rapamycin-asleep companion of mTOR (RICTOR) and mammalian stress-actuated protein kinase-interacting protein 1 (mSIN1 or MAPKAP1) are unique factors in mTORC2 but not mTORC1. mTORC1 substantially regulates cell growth and metabolism, while mTORC2 substantially controls cell proliferation and survival. mTORC2 activates type I insulin- suchlike growth factor receptor IGF- IR) and insulin receptor (InsR) through the tyrosine kinase exertion of mTOR. Also, mTORC2 regulates the actin polarization and endocytosis [6]. Since the catalytic sphere of mTOR resembles that of lipid kinases similar to phosphoinositide 3- kinase (PI3K), mTOR is considered as an atypical protein kinase belonging to the PI3K- related kinase family.

ARRANGEMENT OF mTOR COMPLEX:

mTORC1 structure assembly:

The studies have demonstrated that the mTORC1 structure adopts a dimeric armature with an overall size of (280 300) × (200 210) × (100 130) Å3 [7]. mTOR and LST8 form the core of the mTOR complex that contains raptor and other nonsupervisory proteins [8]. Focal adhesion kinase (FAK) is a tyrosine kinase set up in focal adhesions, intracellular signalling complexes that are formed following the engagement of the extracellular matrix by integrins. The C-terminal FAT region is necessary for localizing FAK to focal adhesions. The crystal-clear structure of FAT resembles two other proteins that are involved in cell adhesion, nascence-catenin and vinculin [9].

mTOR is 2549 amino acids long and it forms several disciplines including the NH2-terminal HEAT (N-HEAT), middle HEAT (M- HEAT), FAT, and kinase sphere with an FRB insertion. The protein sphere HEAT (Huntington, Elongation Factor 3, PR65/A, TOR) is set up in the four miscellaneous eukaryotic proteins for which the sphere is named [10]. FKBP − rapamycin- list (FRB) sphere is the point for Rapamycin to bind and inhibit mTOR. Rapamycin binds the FRB sphere and inhibits the kinase exertion of mTOR [11]. Raptor also contains a HEAT sphere, as well as WD40 and caspase-suchlike sphere. WD40 reprise (WDR) disciplines are β-propeller disciplines that act as protein commerce pulpits in multiprotein complexes. The particularity of the proteins is determined by the sequences outside the reprises themselves. Exemplifications of similar complexes are G proteins (beta subunit is a beta-propeller), TAFII recap factor, and E3 ubiquitin ligase [12].

Caspases (Cysteinedependent Aspartyl-specific proteases) are cysteine peptidases. They're tightly regulated proteins that bear zymogen activation to come active, and formerly active can be regulated by caspase inhibitors. Caspases are substantially involved in apoptosis. Caspases can have places other than in apoptosis, similar to caspase-1 (interleukin-1 beta convertase), involved in seditious processes. The activation of apoptosis can occasionally lead to caspase-1 activation, furnishing a link between apoptosis and inflammation, similar to during the targeting of infected cells [13-15]. A hand motif of WD40 reprises 40 amino acids frequently is ending with a tryptophan-aspartic acid (W-D) dipeptide [16]. The HEAT motifs have conserved Asp and Arg remainders at positions 19 and 25, independently. Raptor may stabilize the dimer by binding the HEAT reprises 11 to 13 in one mTOR and reprises 20 to 22 in another mTOR [17]. Both mTOR and raptor are subordinated to phosphorylation at multiple remainders, which appreciatively or negatively regulates mTORC1 exertion.

mTORC2 structure assembly:

The assembly of mTORC2 follows an analogous pattern to mTORC1. The mortal mTORC2 structure reveals a concave rhombohedral pack with overall confines of 220 × 200 × 130 (Å3) [18]. A dimer of mTOR is located in the core of this complex, while each mTOR heterodimerizes with RICTOR and mSIN1 [19]. RICTOR has an NH2-terminal armadillo ARM) reprise cluster (1000 remainders), and the rest of the RICTOR is largely unshaped [20]. In addition, mSIN1 has a CRIM, a RAS-binding sphere (RBD), and a Pleckstrin homology (PH) sphere [21]. CRIM is a sphere in the middle of the SIN1 protein that's important in the substrate recognition of mTORC2. It's conserved from incentives to humans [22]. Pleckstrin homology sphere (PH sphere) or (PHIP) is a protein sphere of roughly 120 amino acids that occurs in a wide range of proteins similar to Oxysterol binding protein 1 (OSBP0), involved in intracellular signalling or as ingredients of the cytoskeleton. This sphere can bind phosphatidylinositol lipids within natural membranes and proteins similar to the βγ- subunits of heterotrimeric G proteins, and protein kinase C [23]. Armadillo reprise is the name of a characteristic, repetitious amino acid sequence of about remainders in length that's set up in numerous proteins similar as beta-catenin, nascence- importin, plakoglobin, adenomatous polyposis coli (APC). Each armadillo reprise is composed of a brace of nascent helices that form a hairpin structure. Multiple clones of the reprise form what's known as a solenoid structure. The 3-dimensional pack of an armadillo reprise was first observed in the crystal-clear structure of beta-catenin [24].

The RAS-binding sphere (RBD) is an independent sphere of about 75 remainders, which is sufficient for a GTP dependent list of RAS and other G nascence GTPases. The RBD sphere can be present independently or in tandem and it can be set up associated with numerous other disciplines, similar as PDZ, RGS, PID, PH, C1, DH, or protein kinase [25]. During the assembly of mTORC2, the FRB sphere of mTOR binds to mSIN1 and the carboxy-terminal region of RICTOR, while the NH2-terminal portion (remainders 506–516) of RICTOR interacts with the COOH-terminal region (remainders 1186-1218) of M-HEAT of mTOR. Both RICTOR and mSIN1 are responsible for retaining substrates to mTORC2. Also, both RICTOR and mSIN1 have mTOR-independent mates. For illustration, RICTOR interacts with integrin-linked kinase and promotes its phosphorylation of AKT [26], while mSIN1 interacts with RAS and inhibits ERK1/2 phosphorylation [27].

Downstream and upstream of mTORC1:

By suppressing the catabolic pathways and adding the product of proteins, lipids, and nucleotides, mTORC1 plays a central part in regulating the balance between anabolism and catabolism. Then we review how mTORC1 contributes to cell growth. The mTORC1 initiates and promotes protein synthesis by phosphorylation of two crucial effectors p70S6 kinase1 and eIF4E list protein [28]. It directly phosphorylates on its hydrophobic motif point. S6K1 promotes the declination of PDCD4 and also enhances the restatement effectiveness of spliced mRNA by its commerce with SKAR, an element of exon junction complexes. The mTORC1 substrate inhibits restatement by binding with eIF4E to help the assembly of this complex. It phosphorylates various spots to detector dissociation allowing 5' dependent mRNA restatement [29]. This mTORC1 complex induces growth by creating a shift in glucose metabolism from oxidative phosphorylation to glycolysis which facilitates the objectification of nutrients into biomass. It increases the recap factor which helps in driving the expression of several glycolytic enzymes like PFK. It's also said that inheritable hyperactive activation of mTORC1 signalling increases proteasome exertion through enhanced expression of proteasome subunits. mTORC1 activation also triggers a compensatory increase in protein development to make balance proper in increased protein synthesis [30]]. The mTORC1 reliance moves towards adding anabolism which occurs in the presence of regrowth endocrine signals as well as sufficient energy and chemical structure blocks for macromolecular synthesis. mTORC1 is actuated following feeding to promote growth. The cellular pathways upstream of mTORC1 control MTORC1 activation. Multitudinous growth factors are involved like insulin which triggers the AKT-dependent multisite phosphorylation that inhibits TSC by dividing from the lysosomal membrane. Also, RAS signalling also gets actuated by mTORC1 by the Chart kinase ERK that phosphorylates and inhibits TSC2. There are various new mechanisms through Amino acid motes that regulate mTORC1 signalling which have been reported in the identification of Folliculin FNIP 2 complex as a GAP to spark upstream mTORC1 [31].



Fig 1. Show the key components mTORC1and mTORC2.

A: The molecular weight, domains, and phosphorylation sites in key components of mTORC1, including mTOR, LST8, and raptor.

B: The molecular weight, domains, and phosphorylation sites in key components of mTORC2, including TOR, mSin1, and RICTOR.

Downstream and upstream of mTORC2:

mTORC1 helps in cell growth and metabolism while mTORC2 controls proliferation and is primarily involved in survival by phosphorylating different members of the AGC family of protein kinases. The first mTORC2 identified was PKC alpha which regulates the actin cytoskeleton [32].

The most important part which is played by mTORC2 is the phosphorylation and activation of AKT, a role effector of insulin signalling. This AKT induces cell survival, proliferation, and growth with the help of phosphorylation and inhibition of various key substrates which even includes FoxO1/3a transcription factors which is also the metabolic regulator of GSK3 beta [33]. While mTORC2-dependent phosphorylation is required for AKT to phosphorylate some substrates like FoxO1/3a which is dispensable for the phosphorylation of agents such as TSC2. Thus, mTORC2 phosphorylates and activates SGK1 another AGC Kinase, and regulates ion transport as well as cell survivability.



Fig 2. Shows them mTORC1and mTORC2 signalling network.

mTORC2 signalling is substantially regulated by mTORC1 for the presence of a negative feedback circle between mTORC1 and insulin signalling. It phosphorylates and activates Grb10, a negative controller of insulin/ IGF 1 receptor, signalling upstream of AKT and mTORC2 where S6K1 suppresses mTORC2 activation with the help of phosphorylation-dependent declination of insulin receptor substrate 1. This negative feedback regulation of PI3K and mTORC2 signalling by mTORC1 has various impacts on the pharmacological targeting of mTOR in cancer 1.

INTER-RELATION OF mTOR SIGNALLING PATHWAYS AND TUMOURS:

Tumour Proliferation:

mTOR acts as a major controller of growth and division of the cell. But tumour cells grow, metastasize, exhibit aggressive behaviour and invade new healthy tissues due to the signals delivered by the abnormally active mTOR [34]. mTOR is always stimulated in tumours for the conservation of growth, for survival of cells and for their proliferation which plays a significant part in tumour cell biology. The main activators of mTORC1 are PI3K/ PTEN/ AKT/ TSC and posterior mutations in these genes can lead to abnormal growth of cells and nasty tumours.

Phosphatase and Tensin Homolog (PTEN) is a phosphatase enzyme in humans and is decoded by the PTEN gene. It's a classical tumour suppressor gene located in the 10q23 region of chromosome 10 garbling for a 403- amino acid multifunctional protein [35]. Hou, *et al*. [36] discovered that mutations in the PTEN gene led to abnormal activation of the PI3K/ PTEN pathway causing hepatic cell melanoma (HCC) whereas omission of PTEN gene leads to immunosuppression and possibility of tumour progression and irruption increases. In the case of liver cancer, the PI3K/ PTEN/ AKT/ mTOR signalling pathway is actuated and is involved in tumour

irruption and metastasis by over- regulating matrix metallopeptidase 9(MMP-9) [37]. Xie, *et al*. [38] set up that liver kinase B1 (LKB1) gene mutation or extracellular growth signal could spark mTORC1. The exertion of the ring cutlet protein 168(RNF168) is inhibited by mTORC1 and it promotes its declination by phosphorylating the 60th serine of RNF168. This will significantly devalue the ubiquitination revision of histone H2A and H2A family member X(H2AX) proteins after DNA damage, which will inhibit the response to DNA damage leading to the creation of nasty cell metamorphosis and cancer. Deng, *et al*. [39] reported that the ubiquitination of RAS homolog amended in the brain (RHEB) was regulated by growth factor signals similar to epidermal growth factor (EGF) and insulin- such as growth factor (IGF). Ubiquitinated RHEB inhibits its exertion by promoting RHEB binding to tuberous sclerosis complex 2(TSC2), leading to the inhibition of mTORC1 expression. In addition to the mTORC1 pathway, the mTORC2 pathway plays an important part in the regulation of the circumstance and development of tumour cells. Kovalski, *et al*. [40] proved that to promote the exertion of mTORC2 kinase, RAS mutations bind to mTOR of mTORC2 and mitogen-activated protein kinase- associated protein 1 (MAPKAP1), therefore initiating downstream proliferative cell cycle recap programs. Active AKT phosphorylates TSC2 and inhibits the TSC complex, a GTPase- cranking protein (GAP) complex conforming of TSC1/2 and TRE2- BUB2- CDC16 sphere family member 7(TBC1D7) [41].

Tumour Metabolism:

The activation of mTOR takes place when sufficient nutrients are handed which promotes anabolism, energy storehouse and utilisation. In the failure of the nutrients, the body inhibits the activation of mTOR to keep cell material and energy stable. When nutrients are scarce, the body must inhibit the activation of mTOR to keep cell material and energy stable. Pyruvate kinase (PK) is involved in sugar metabolism while adipose acid synthase (FASN) is involved in the synthesis of adipose acid (FA).

The major medium to induce new lipid synthesis and promote tumour proliferation in bone cancer cells, occurs through the AKT/ PI3K/ mTORC1/ sterol nonsupervisory element- binding protein (SREBP) pathway [42]. There's a connection between SREBP and Pyruvate kinase PK) i.e., involved in sugar metabolism. Tao, *et al*. [43] set up that down- regulating the expression of pyruvate kinase M2 (PKM2) deactivates the AKT/ mTOR signalling pathway, thereby reducing the expression of SREBP-1c. The reduced expression position of SREBP- 1c inhibits the generation of FA by inhibiting the recapitalization of the FASN gene, performing in the inhibited growth of tumour cells. Guri, *et al*. [44] set up that mTORC2 promoted the product of sphingomyelin and cardiolipin in HCC. In addition, Di Malta, *et al*. [45] reported that the up-regulated recap factor enhancer (TFE) gene can spark the Rag GTPase/ mTORC1 pathway and as a consequence the cells can now more absorb nutrients to maintain physiological functions. In tumour cells, this pathway is frequently over-activated to meet the nutritive requirements of the fleetly growing tumour cells.

On the one hand, sphingomyelin and cardiac phospholipids are both structural factors of the cell and on the other hand, the metabolism and transport of cardiac phospholipids contribute to the proper functioning of mitochondria, so they must be supplied in large amounts in fleetly proliferating tumour cells [46]. Ericksen, *et al*. [47] demonstrated that the reduction of fanned- chain amino acid (BCAA) corruption promotes the development of tumours by adding mTORC1 exertion. The enzyme in the BCAA catabolism correlates with irruption of tumour. The mitochondrial BCAT isoenzyme is primarily responsible for initiating the BCAA catabolism process. Therefore, the inhibition of BCAA catabolism in liver tumour tissues is a major medium of mTORC1 tumour activation. Shi, *et al*. [48] set up that there was an increase in expression of adenosine A2a receptor (A2aR) in gastric cancer (GC) tissues and the expression of A2aR was appreciatively identified with the GC stage. It was later realised that adenosine activates the PI3K/ AKT/ mTOR signalling pathway by binding to A2aR, which eventually promotes the progression of GC. These studies demonstrate that the mTOR signalling pathway is nearly related to tumour metabolism and give theoretical support for the combined operation of mTOR inhibitors and some medicines that intrude with tumour metabolism. These studies indicate that the mTOR signalling pathway is nearly related to tumour metabolism and give theoretical support for the combined operation of mTOR inhibitors and some medicines that intrude with tumour metabolism.



Fig 3. Summarizes how the over activation of mTORC1 can promote tumour formation, proliferation, and metastasis, while mTORC2 can regulate the expression of mTORC1 through the mTORC2/AKT/TSC/RHEB pathway.

Pathway1: The extracellular growth signals and intracellular LKB1 mutations activate mTORC1, which reduces the ubiquitination of histone H2A and H2A after DNA damage by phosphorylating RNF168. This can lead to damage to DNA repair and promote the formation of tumors. Pathway 2: The ubiquitination of RHEB reduces RHEB activity by promoting RHEB binding to TSC2. The down regulation of RHEB reduces the activation of mTORC1, leading to the inhibition of tumour growth. Pathway 3: TRAF2 and Otud7B respectively regulate mTORC1/2 activity by up-regulating ordown-regulating the ubiquitination level of GbetaL of mTORC2. TRAF2 enhanced the activity of mTORC1 and inhibited the activity of mTORC2. Although down-regulation of mTORC2expression inactivates the AKT/TSC/RHEB/mTORC1 pathway, overall mTORC1 activity is enhanced. However, Otud7Bhas the opposite effect on TRAF2. Pathway 4: Mutated RAS binds mTOR and MAPKAP1 of mTORC2 to promote mTORC2 expression. The up-regulation of mTORC2 promotes tumour proliferation through the AKT/TSC/RHEB//mTORC1 pathway. Pathway 5: Deletion of the PTEN gene induces the expression of B7-H1 to increase tumour progression and invasion. Pathway 6: The PI3K/PTEN/AKT/mTOR pathway is involved in the invasion and metastasis of liver cancer by up regulating MMP-9.

Immune Cells:

Tumours suppress the vulnerable system's capability to fete and kill tumour cells. The vulnerable cells include T cells, natural killer cells and dendritic cells and macrophages. T cells enter the thymus from the bone gist, where they separate into αβ T cells and γδ T cells. Yang, *et al.* [49] proved that RAPTOR omission in mTORC1 would break the remodelling process of oxidative metabolism and glucose metabolism during T cell isolation. This touched off the product of ROS, which disturbs the isolation of αβ T cells and increases the isolation of γδ T cells. The downregulation of the PI3K/ mTOR pathway limits the specialisation of Treg cells and inhibits the isolation and activation of traditional T cells.



Fig 4. Shows the interaction between tumour metabolism and the mTOR signalling pathway. The above image represents the following pathways.

Pathway 1: In bladder cancer, down-regulation of PKM2 expression reduces SREBP-1expression through inactivated AKT/TSC/RHEB/mTORC1 pathway. The down-regulation of SREBP-1c inhibits FA generation by inhibiting FASN transcription, leading to the inhibition of tumour growth. Pathway 2: Up-regulation of TEF in tumours activates the RAS/ERK/TSC/RHEB/mTORC1 pathway. Activation of this pathway will promote the uptake of nutrients by tumour cells to meet the needs of the rapid growth of tumours. Pathway 3: HCC can increase sphingomyelin and cardiolipin production by activating mTORC2. Large amounts of sphingomyelin and cardiolipin are used to assemble cell membranes, which also meet the needs of rapid tumour proliferation. Pathway 4: The accumulation of BCAA can promote the occurrence and development of tumours by activating mTORC1. Pathway 5: A2aR, which is highly expressed in gastric cancer, adenosine binds to it and activates the PI3K/AKT/mTORC1 pathway. Pathway 6: Inbreastcancer, FFAs promotes tumour proliferation and metastasis by activating the PI3K/AKT/mTORC1 pathway. Pathway 7: The PI3K/AKT/mTORC1/SREBP pathway promotes breast cancer proliferation by inducing new lipid synthesis.

The mTOR signalling pathway plays a major part in isolation and functions of dendritic cells and natural killer cells. DC has a strong antigen representation capability, and NK cells are important vulnerable cells in the body. Wang, *et al.* [50] proved NK cells are regulated by mTORC1 and mTORC2 where mTORC2 regulates the NK cell negatively by inhibiting the signal transducer and cranking recap 5 (STAT5)/ solute carrier family 7member 5 SLC7A5) axes. mTORC1 regulates the exertion of mTORC2 appreciatively by maintaining the signalling pathway CD122- intermediated interleukin (IL)- 15. Chen, *et al.* [51] concluded that after the treatment with mTOR inhibitors, the apoptosis of DC-deduced bone gist mononuclear (BMM) was dropped. They also set up that BMM cell-dedicated DCs had better antigen donation capabilities and thus, mTOR inhibitors can enhance the efficacy of tumour immunotherapy by extending the life span of DC and perfecting antigen donation.

M1- type macrophages kill tumour cells in multiple ways, while M2- type macrophages promote the circumstance, aggressiveness, irruption and metastasis of the tumours. Zhihua, *et al.* [52] reported that the expression of micro RNA (miRNA)- 30c was significantly reduced in GC. The downregulation of miRNA- 30c will reduce mTOR exertion and glycolysis

in tumour related macrophages. This will ultimately promote GC growth and metastasis by inhibiting the isolation and function of M1- type macrophages.

mTOR INHIBITORS:

mTOR is a member of the phosphatidylinositol-3-kinase-related kinase family (PIKKs) and members in this family have further than 500 amino acids and have a kinase sphere at their C- boundary that's similar in sequence to phosphatidylinositol-3-kinase (PI3K) [53]. mTOR is a protein kinase that phosphorylates threonine and serine remainders in its substrates, despite having the sequence hand of a lipid kinase. In cells, the catalytic subunits of two multi-protein complexes called mTOR complex 1 (mTORC1) and complex 2 (mTORC2) act as the catalytic subunits of mTOR [54]. TORC1 is a crucial downstream element of the PI3K/ AKT pathway, relaying signals from tumour suppressors similar as PTEN, LKB1, and TSC1/ 2 as well as oncoproteins similar as PI3K and AKT [55]. Downstream mTORC1 controls cellular biogenesis through regulation of protein synthesis and development. It phosphorylates eIF4E binding protein 1(4EBP1) and ribosomal protein S6 kinase (S6K), two factors involved in restatement inauguration [56]. The mTORC2 is also involved in the PI3K/ AKT pathway but its function is independent of mTORC1. It phosphorylates and stimulates AKT activation; hence plays a critical part in AKT intermediated cell survival [57].

First generation mTOR Inhibitors:

Rapamycin, also known as sirolimus, is the first generation mTOR inhibitor. It was originally developed as an immunosuppressive drug because of its implicit capability to inhibit T- cell activation. In 1997, the FDA approved it for use in transplantation to reduce allograft rejection and in 2003 for use in coronary roadway stents to help restenosis [58]. Though the anticancer effect of Rapamycin was discovered in the early 1980s, it wasn't used in cancer remedy until the late 1990s, when various analogues of the medicine, known as rapalogs, were produced. Bioavailability of Rapamycin is confined by its incapability to dissolve in water. Primary focus of the exploration was on adding its pharmacokinetics and stability. Still, because the medicine must bind to FKBP12 and mTOR on both sides, there isn't important implicit enhancement. All rapalogs are made by replacing the hydrogen at C-40-O position with different halves. Temsirolimus was the first rapalog to be approved by the FDA for cancer treatment in 2007 [59].

It was delicate to figure out a need for fresh types of mTOR inhibitors in multitudinous preclinical models because of the selectivity and energy in anticancer conditioning. Still, the remedial operation of rapalogs in cancer treatment has had mixed results. Rapalogs are effective in the treatment of many cancers, similar as renal cell melanoma and mantle cell melanoma, but not in the treatment of the vast maturity of solid tumours [60]. Rapamycin is the prototype of the first generation of mTOR inhibitors [61]. It's a macrocyclic lactone which contains two binding halves that are essential for its action. The mechanisms of rapalog resistance are complicated [62]. De novo medicine resistance is caused by inheritable changes of proteins involved with the mTOR signalling pathway in cancer cells, but the main reason is probably due to the fact that the treatment doesn't incontinently beget cell death [63]. Rapamycin convinced stress responses include reduction in protein synthesis and the induction of autophagy, both of which are defensive mechanisms for cells to survive in stressful situations [64]. As a result, the immediate effect of the medicine is cytostatic rather than cytotoxic. In addition, inhibiting mTORC1 switches off an S6K-dependent negative feedback circle in cancer cells that downregulates PI3K/ AKT upstream signalling, performing in increased PI3K/ AKT exertion that promotes cell survival [65].

Second generation mTOR inhibitors:

To get beyond the limitations of rapalogs in cancer therapy, two methods have been developed. The first system includes combining the medicines with cytotoxic agents. For illustration, rapalogs are presently being tested in combination with chemotherapeutic agents similar as Paclitaxel and Carboplatin to treat advanced ovarian cancer and metastatic carcinoma. Likewise, in endocrine malice, the medicines are used in confluence with hormonal remedy to stimulate the cancer cells for the treatment [66]. The alternate system involves developing inhibitors that target either both PI3K and mTOR contemporaneously or widely. mTOR acts as the catalytic subunit for both mTORC1 and mTORC2, hence it inhibits the kinase exertion which is likely to affect both complexes and contemporaneously block the mTORC2 dependent activation of AKT [67].

The structure of the ATP binding fund of the kinases is used in the development of PI3K and mTOR kinase inhibitors, which use small composites to contend with ATP for the list fund. As a result, these inhibitors are

pertained to as ATP competitive inhibitors. Because mTOR and PI3K have analogous sequences, multitudinous ATP competitive PI3K inhibitors have been discovered to have varying degrees of mTOR inhibitory action. These inhibitors were constantly utilised as prototypes for binary inhibitors of PI3K and mTOR. PI- 103 is a pyrimidine outgrowth that was firstly created as apan-PI3K asset but was latterly discovered to inhibit PI3K- related kinases, including mTOR. With an IC50 of 2 – 3 nM, PI- 103 inhibits multiple isoforms of PI3K, but is less picky for mTORC1 and mTORC2 with IC50 of 20 nM and 83 nM, independently [68]. GDC- 0980 has an analogous IC50 for both PI3K and mTOR [69]. GNE493, GNE- 477, and PF- 04691502, which are pickier for PI3K than for mTOR have been created, grounded on the structure of PI- 103 [70]. BEZ- 235, an imidazoquinolinone secondary, belongs to the same class of inhibitors as BGT226 and GKS2126458. BEZ- 235 inhibits multiple PI3K and mTOR isoforms with an IC50 of 5 nM. GKS2126458 is a largely effective PI3K/ mTOR binary asset. PI3K has an IC50 of 0.04 nM, while mTORC1 and mTORC2 have IC50s of 0.18 and 0.3 nM, independently. Anothernon-pyrimidine secondary with strong energy for PI3K and mTOR is XL765 which is a quinoxaline outgrowth [71].

Dual mTOR Inhibitors:

While contemporaneously targeting PI3K and mTOR, the limitations of rapalogs in blocking PI3K/ AKT signalling, the implicit toxin of these inhibitors is a major issue, given the diversity of conditioning of distinct PI3K isoforms. Inhibitors that are more specific for mTOR are study to be better permitted than binary inhibitors [72]. Likewise, because mTORC2 is essential for AKT activation, blocking this complex using mTOR kinase inhibitors is likely to reduce AKT'spro-survival exertion [73]. Both OSI- 027, a triazine outgrowth, and AZD2014, a pyrimidine outgrowth analogous to AZD8055, have IC50s below 4 nM and are picky for mTOR over PI3K by> 300 pack. INK128, a pyrimidine outgrowth analogous to PP242 and PP30, has a 1 nM IC50 and is> 200 times further picky for mTOR than PP242 and PP30 [74]. Torin 1, a quinoline secondary grounded on BEZ- 235, exhibits an IC50 of lower than 10 nM and is further than, 000 times further specific than BEZ- 235 [75]. The new inhibitors have a high efficacy and selectivity, icing effective and specific down regulation of mTORC1 and mTORC2, while keeping PI3K unchanged. In both cell grounded and beast studies, the binary inhibitors, similar as BEZ-235 and GSK2126458, are effective in inhibiting PI3K, mTORC1 processes and mTORC2-dependent processes, while the mTOR picky inhibitors, similar as OSI- 027 and INK128, specifically reduce mTORC1 and mTORC2 exertion [76]. In comparison with rapalogs, PI3K/ mTOR and mTOR picky inhibitors are more potent in blocking cell proliferation and induction of apoptosis in numerous civilized cancer cells and in tumour xenograft models, including some rapamycin resistant tumours [77]. Several of this new generation of inhibitors have successfully made into clinical trials, among which BEZ235, INK128, AZD2014 and XL765 are presently in phase II trials for efficacy studies in the treatment of different types of cancer diseases. In phase I studies, these inhibitors displayed toxins that were tolerable and manageable, which, to a certain degree, alleviates the safety concern associated with the new generation medicines.

Third generation mTOR inhibitors:

Recently, Rapalink-1, a drug that links rapamycin and the mTOR kinase asset MLN0128, has been developed with excellent therapeutic efficacy against bone cancer cells carrying mTOR resistance mutations. Rapalink-1, with its potent anticancer exertion, reduces the size of tumours resistant to first- or alternate- generation mTOR inhibitors. These results suggest that a variety of recently discovered mTOR inhibitors are effective in numerous tumours. In the future, these medicines can be designed for clinical exploration, so that they can be used for clinical treatment [77]. In addition, numerous mTOR inhibitors are having different mechanisms of action have been developed, some of which are witnessing clinical trials in a variety type of mortal cancer.

CONCLUSION:

The mTOR signalling pathway is nearly related to tumours, and it's nearly related to its cell growth, metabolism, apoptosis and autophagy. For illustration, the mTOR signalling pathway can affect gene recap and protein synthesis to regulate cell growth and proliferation and play an important part in tumour metabolism. A number of studies have shown that a variety of new mTOR inhibitors show high anti-tumour exertion in clinical studies, and the use of mTOR inhibitors in combination with other anti-tumour medicines have a significant effect. This review describes the relationship between the mTOR signalling

Table 1. Examples of mTOR inhibitors with proposed indication.

Generation	Compoundname	Status	Indicationstestedinclinicaltrials
1st	Rapamycin	Approved(1999)	Acute renal allograft rejection/ Restenosis
1st	Everolimus	Approved(2003)	Allograft rejection
1st	Temsirolimus	Approved(2007)	Mantlecelllymphoma
2nd	AZD8055	PhaseI/II	Advanced solid tumours, Hepatocellular carcinoma
2nd	INK128	PhaseI/II	Advanced solid tumours, Multiplemyeloma
2nd	OSI027	PhaseI/II	Advanced solid tumours, Lymphoma
DI	BEZ235	PhaseI/II	Metastaticbreastcancer
DI	GSK2126458	PhaseI/II	Advanced solid tumours, Lymphoma
DI	XL765	PhaseI/II	Metastaticbreastcancer
3rd	RapaLinks	Approved(2016)	_

pathway and tumour cell growth and proliferation. This review also introduces exploration progress on the operation of mTOR inhibitors in tumours, which indicates the significance of the mTOR signalling pathway in the tumour fields.

However, the role of the mTOR signalling pathway has not been easily studied, and although mTOR inhibitors can inhibit tumour cell growth, their capability to induce tumour cell death is limited. The mechanisms of tumours are complex and involve numerous signalling pathways. Inhibition of certain signalling pathways may lead to feedback activation of other signalling pathways, so although mTOR asset combination remedy is more effective, its effect is limited. In addition, clinical trials have demonstrated that the side goods of treatment with mTOR inhibitors cannot be ignored. It's hoped that the mechanisms of the mTOR signalling pathway can be easily studied in the future, and also picky mTOR inhibitors can be developed to improve anti-tumour exertion and reduce side effects. Recent studies reveal that tumour organoids may help in medicine testing. Tumour organoids may be used to test the response of a given tumour to mTOR inhibitors. Alternatively, case-deduced tumour grafts may be scattered to creatures, followed by testing their response to mTOR inhibitors. It would be of interest to determine if these arising technologies are clinically applicable.

ACKNOWLEDGEMENT:

The authors are thankful to the Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, for providing all the library facilities to collect and complete the literature review on mTOR signalling Pathway.

REFERNCES:

1. Yancun Y, *et al*. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res, 2016; 26(1): 46-65.
2. Robert SA, David MS. mTOR signalling in growth, metabolism, and disease. Cell, 2017; 168(6): 960-976.
3. Thomas NP. TOR-dependent control of autophagy: biting the hand that feeds. Cur Opin Cell Biol, 2010; 22(2): 157-168.
4. Binghong G, *et al*. piRNAs: biogenesis and their potential roles in cancer. Cancer Metastasis Rev, 2020; 39(2): 567-575.
5. Roberto Z, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol, 2011; 12(1): 21-35.
6. Estela J, *et al*. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol, 2004; 6(11): 1122-1128.
7. Huirong Y, *et al*. 4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1. Protein Cell, 2016; 7(12): 878-887.
8. Yip CK, *et al*. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell, 2010; 38(5): 768-774.
9. Ikuko H, Vuori K, Liddington RC. The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struc Biol, 2002; 9(2): 101-106.
10. Groves MR, *et al*. The structure of the protein phosphatase 2A PR65/A subunit reveals the

conformation of its 15 tandemly repeated HEAT motifs. Cell, 1999; 96(1): 99-110.
11. Sharma V, Panwar A, Sharma A, Pung V, *et al*. A comparative molecular dynamic simulation study on potent ligands targeting mTOR/FRB domain for breast cancer therapy. Biotechnol Appl Biochem, 2022, 69(4):1339-1347.
12. Li D, Roberts R. Human Genome and Diseases: WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci, 2001; 58(14): 2085-2097.
13. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ, 1999; 6(11): 1028-1042.
14. William CE, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem, 1999; 68(1): 383-424.
15. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol, 2004; 14(4): 184-193.
16. Neer EJ, *et al*. Erratum: the ancient regulatory-protein family of WD-repeat proteins. Nat, 1994; 371(6500): 812-812.
17. Aylett, Christopher HS, *et al*. Architecture of human mTOR complex 1. Sci, 2016; 351(6268): 48-52.
18. Chen X, *et al*. Cryo-EM structure of human mTOR complex 2. Cell Res, 2018; 28(5): 518-528.
19. Karuppasamy M, *et al*. Cryo-EM structure of *Saccharomyces cerevisiae* target of rapamycin complex 2. Nat Commun, 2017; 8(1): 1-10.
20. Zhou P, *et al*. Defining the domain arrangement of the mammalian target of rapamycin complex component Rictor protein. J Comput Biol, 2015; 22(9): 876-886.
21. Liu P, *et al*. PtdIns (3, 4, 5) P3-dependent activation of the mTORC2 kinase complex. Cancer Discov, 2015; 5(11): 1194-1209.
22. Kataoka S,*et al*. 1H, 15N and 13C resonance assignments of the conserved region in the middle domain of S. pombe Sin1 protein. Biomol NMR Assign, 2015; 9(1): 89-92.
23. Wang DS, Gerry S. The association of the C-terminal region of β1σII spectrin to brain membranes is mediated by a PH domain, does not require membrane proteins, and coincides with an inositol-1, 4, 5 trisphosphate binding site. Biochem Biophysic Res Commun, 1995; 217(2): 608-615.
24. Huber AH,Nelson WJ, Weis WI. Three-dimensional structure of the armadilo repeat region of beta-catenin. Cell, 1997; 90: 871-882.
25. Ponting CP. Raf-like RAS/Rap-binding domains in RGS12-and still-life-like signalling proteins. J Mol Med, 1999; 77(10): 695-698.
26. Donald M, Paul C, *et al*. RICTOR and integrin-linked kinase interact and regulate AKT phosphorylation and cancer cell survival. Cancer Res, 2008; 68(6): 1618- 1624.
27. Schroder WA, *et al*. Human Sin1 contains RAS-binding and pleckstrin homology domains and suppresses RAS signalling. Cell Signal, 2007; 19(6): 1279-1289.
28. Choo AY, *et al*. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci, 2008; 105(45): 17414-17419.
29. Ben-Sahra I, *et al*. Stimulation of de novo pyrimidine synthesis by growth signalling through mTOR and S6K1. Sci, 2013; 339(6125): 1323-1328.
30. Zhao J,*et al*. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci, 2015; 112(52): 15790-15797.
31. Dibble CC, Lewis CC. Regulation of mTORC1 by PI3K signalling. Trends Cell Biol, 2015; 25(9): 545-555.
32. Angliker N, Markus AR. *In vivo* evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons. Bioarchitec, 2013; 3(4): 113-118.
33. Artham S, *et al*. Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury. Pharmacol Res, 2019; 141: 249-263.
34. Hsieh AC, *et al*. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature, 2012; 485(7396): 55-61.
35. Nathan N, *et al*. Mosaic disorders of the PI3K/PTEN/AKT/TSC/mTORC1 signalling pathway. Dermatol Clin, 2017; 35(1): 51-60.
36. Hou W, *et al*. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett, 2014; 8(3): 1249-1254.

37. Chen J, *et al*. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res, 2009; 39(2): 177-186.
38. Xie X, *et al*. The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168. Nat Cell Biol, 2018; 20(3): 320-331.
39. Deng LU, *et al*. Ubiquitination of RHEB governs growth factor-induced mTORC1 activation. Cell Res, 2019; 29(2): 136-150.
40. Kovalski JR, *et al*. The functional proximal proteome of oncogenic RAS includes mTORC2. Mol Cell, 2019; 73(4): 830-844.
41. Potter CJ, Laura GP, Tian X. AKT regulates growth by directly phosphorylating Tsc2. Nat Cell Biol, 2002; 4(9): 658-665.
42. Ricoult SJH, *et al*. Oncogenic PI3K and K-RAS stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene, 2016; 35(10): 1250-1260.
43. Tao T, *et al*. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. J Cell Physiol, 2019; 234(3): 3088-3104.
44. Guri Y, *et al*. mTORC2 promotes tumourigenesis via lipid synthesis. Cancer Cell, 2017; 32(6): 807-823.
45. Di MC, *et al*. Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. Sci, 2017; 356(6343): 1188-1192.
46. Zhu X, *et al*. The rs391957 variant cis-regulating oncogene GRP78 expression contributes to the risk of hepatocellular carcinoma. Carcinogenesis, 2013; 34(6): 1273-1280.
47. Ericksen RE, *et al*. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumour development and progression. Cell Metab, 2019; 9(5): 1151-1165.
48. Ericksen RE, *et al*. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumour development and progression. Cell Metab, 2019; 29(5): 1151-1165.
49. Yang K, *et al*. Metabolic signalling directs the reciprocal lineage decisions of αβ and γδ T cells. Sci Immunol, 2018; 3(25):9818.
50. Wang F, *et al*. Crosstalk's between mTORC1 and mTORC2 variegate cytokine signalling to control NK maturation and effector function. Nat Commun, 2018; 9(1): 1-17.
51. Chen YL, *et al*. mTOR inhibitors can enhance the anti-tumour effects of DNA vaccines through modulating dendritic cell function in the tumour microenvironment. Cancers, 2019; 11(5): 617.
52. Zhihua Y, *et al*. Hypoxia decreases macrophage glycolysis and M1 percentage by targeting microRNA-30c and mTOR in human gastric cancer. Cancer Sci, 2019; 110(8): 2368-2377.
53. Lempiäinen H, Thanos DH. Emerging common themes in regulation of PIKKs and PI3Ks. The EMBO J, 2009; 28(20): 3067-3073.
54. Hara K, *et al*. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 2002; 110(2): 177-189.
55. Laplante M, David MS. mTOR signalling in growth control and disease. Cell, 2012; 149(2): 274-293.
56. Ma XM, John B. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol, 2009; 10(5): 307-318.
57. Huang J, Brendan DM. A complex interplay between AKT, TSC2 and the two mTOR complexes. Biochem Soc Transac, 2009; 37(1): 217-222.
58. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc, 2003; 35(3): 7S-14S.
59. Kwitkowski VE, *et al*. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist, 2010; 15(4): 428-435.
60. Carew JS, Kevin RK, Steffan TN. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol, 2011; 6(1): 17-27.
61. Lawrence JC, *et al*. Modulation of the protein kinase activity of mTOR. TOR, 2004; 199-213.
62. Huang S, Mary-Ann B, Peter JH. Rapamycins: mechanisms of action and cellular resistance. Cancer Biol Ther, 2003; 2(3): 222-232.
63. Hung CM, *et al*. MTOR-dependent cell survival mechanisms. *Cold Spring Harbperspect Biol, 2012; 4(12):* a008771.
64. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumourigenesis. J Cell Biol, 2004; 167(3): 399-403.
65. Mohamed A, *et al*. Targeted therapy for breast cancer. Am J Pathol, 2013; 183(4): 1096-1112.
66. Zaytseva YY, et al. mTOR inhibitors in cancer therapy. Cancer Lett, 2012; 319(1): 1-7.
67. Fan QW, *et al*. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006; 9(5): 341-349.

68. Sutherlin DP, *et al*. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011; 54(21): 7579-7587.
69. Yuan J, *et al*. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumour activity. Mol Cancer Ther, 2011; 10(11): 2189-2199.
70. Yu, Peiwen, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumour models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther, 2014; 13(5): 1078-1091.
71. Pallet N, Christophe L. Adverse events associated with mTOR inhibitors. *Expert Opin Drug Saf,* 2013; 12(2): 177-186.
72. Shor B, *et al*. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle, 2009; 8(23): 3831-3837.
73. Schenone S, *et al*. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem, 2011, 18(20): 2995-3014.
74. Thoreen CC, *et al*. Correction: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem, 2020; 295(9): 2886.
75. Cassell A, *et al*. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia, 2012; 14(11): 1005-1014.
76. Bhagwat SV, *et al*. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther, 2011; 10(8): 1394-1406.
77. Kuroshima K, *et al*. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. Cancer Sci, 2020; 111(5): 1607-1618.

Conflict of Interest: None
Source of Funding: Nil
Paper Citation: Panda E*, Bhanja J, Rana R, Chowdhury B, Ravi Kumar BVV. mTOR Signalling pathway in Drug Discovery of Anticancer agents.. J Pharm Adv Res, 2023; 6(4): 1839-1852.